RELUGOLIX

GnRH Antagonist

Brand names: Orgovyx

Oral

Mechanism of Action

12.1 Mechanism of Action Relugolix is a nonpeptide GnRH receptor antagonist that competitively binds to pituitary GnRH receptors, thereby, reducing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and consequently testosterone.

Indications

See full prescribing information

FDA Warnings

5 WARNINGS AND PRECAUTIONS QT/QTc Interval Prolongation: Androgen deprivation therapy may prolong the QT interval ( 5
Providers should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, or frequent electrolyte abnormalities and in patients taking drugs known to prolong the QT interval
2 Hypersensitivity Reactions ORGOVYX is contraindicated in patients with severe hypersensitivity to relugolix or any of the product components [see Contraindications ( 4 )]
Hypersensitivity reactions, including pharyngeal edema and other serious cases of angioedema, have been reported postmarketing in patients treated with ORGOVYX

Known Side Effects

9 documented side effects by frequency

Fatigue

>10%

Weakness

1-10%

Joint Pain

0.1-1%

Diarrhea

0.1-1%

Dizziness

0.1-1%

Constipation

0.1-1%

Weight Gain

0.1-1%

Insomnia

0.1-1%

Muscle Pain

0.1-1%

Community Discussions

No community discussions found for RELUGOLIX yet.

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Oral